<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855634</url>
  </required_header>
  <id_info>
    <org_study_id>TUM-Chir-001/2009</org_study_id>
    <nct_id>NCT00855634</nct_id>
  </id_info>
  <brief_title>Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München</brief_title>
  <acronym>PaMeViTUM</acronym>
  <official_title>Extended Versus Standard Resection in Two Cohorts of Patients With Adenocarcinoma of the Pancreas: Minimal Metastatic Disease or Venous Infiltration - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PaMeViTUM is a mono-centric prospective randomized controlled trial that compares different&#xD;
      operating procedures in patients with pancreatic cancer and minimal metastatic disease or&#xD;
      venous infiltration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PaMeViTUM is a mono-centric prospective randomized controlled trial comparing different&#xD;
      operating procedures in patients with pancreatic cancer and minimal metastatic disease or&#xD;
      venous infiltration. Patients will be randomized intraoperatively after fulfilling all&#xD;
      inclusion criteria (in particular: suspicion of cancer of the pancreas and an intraoperative&#xD;
      histologically proven diagnosis of pancreatic adenocarcinoma; intraoperative assessment of&#xD;
      tumor as potentially locally respectable). If no metastases and no infiltration of the portal&#xD;
      vein are detected during the operation, the standard resection will be performed (for tumors&#xD;
      of the pancreatic head: (pylorus-preserving) pancreaticoduodenectomy; for tumors of the&#xD;
      pancreatic body/tail: distal (left) pancreatic resections; for tumors of the head and&#xD;
      body/tail: total pancreatectomy). In the case of tumor infiltration of the pyloric region or&#xD;
      the distal stomach, a classical pancreaticoduodenectomy will be performed.&#xD;
&#xD;
      If the patient has pancreatic cancer with minimal metastatic disease (COHORT 1) and fulfills&#xD;
      all inclusion criteria, she/he will be randomized into one of the following arms:&#xD;
&#xD;
        -  Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver&#xD;
           metastasis/metastases&#xD;
&#xD;
        -  Arm 2 (control): exploration and/or gastroenterostomy and/or&#xD;
           hepaticojejunostomy/choledochojejunostomy&#xD;
&#xD;
      If there are no liver metastases, following mobilization (and potentially also the dissection&#xD;
      of the pancreas at the pancreatic head), the extension of the tumor towards the superior&#xD;
      mesenteric/splenic/portal vein is examined. If there is venous infiltration (COHORT 2) and&#xD;
      the patient fulfills the inclusion criteria, she/he will be randomized into one of the&#xD;
      following arms:&#xD;
&#xD;
        -  Arm 1 (intervention): resection of the primary tumor with resection of the portal vein&#xD;
           (and/or superior mesenteric vein/splenic vein (SMV/SV)&#xD;
&#xD;
        -  Arm 2 (control): resection of the primary tumor with dissection of the portal vein&#xD;
           (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to&#xD;
           these veins; no venous resection The aim of this study is to demonstrate that an&#xD;
           extension of the resectability criteria in patients with pancreatic cancer and 1)&#xD;
           minimal metastatic disease OR 2) venous infiltration improves overall survival. A&#xD;
           secondary aim of the study is to prove that resection in these patient cohorts improves&#xD;
           quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol planned interim analysis after two years showed very low recruitment in cohort 1 and&#xD;
    low recruitment in cohort 2.&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival</measure>
    <time_frame>Additional 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">355</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 1 (minimal metastatic disease):&#xD;
Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases&#xD;
Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 2 (venous infiltration):&#xD;
Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)&#xD;
Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection of metastases</intervention_name>
    <description>resection of the primary tumor, followed by resection of the liver metastasis/metastases</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection of infiltrated veins</intervention_name>
    <description>resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suspicion of cancer of the pancreas and an intraoperative histologically proven&#xD;
             diagnosis of pancreatic adenocarcinoma.&#xD;
&#xD;
          -  intraoperative assessment of tumor as potentially locally resectable&#xD;
&#xD;
          -  COHORT 1: Minimal metastatic disease&#xD;
&#xD;
          -  COHORT 2: Venous infiltration&#xD;
&#xD;
          -  ability to sign the informed consent.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70.&#xD;
&#xD;
          -  Life-expectancy of more than 3 months.&#xD;
&#xD;
          -  able to attend follow-up.&#xD;
&#xD;
          -  no previous or concurrent malignancy diagnoses, except non-melanoma skin cancer and in&#xD;
             situ carcinoma of the cervix.&#xD;
&#xD;
          -  no serious medical, psychological, familial, sociological or geographical conditions&#xD;
             potentially hampering compliance with the study protocol and follow-up.&#xD;
&#xD;
          -  patients older than 18 years.&#xD;
&#xD;
          -  no pregnant or lactating women.&#xD;
&#xD;
          -  preoperative evaluation by thin-sliced CT scans with:&#xD;
&#xD;
          -  No evidence of substantial extra-pancreatic disease, i.e. no evidence of malignant&#xD;
             ascites, extended liver metastasis (&gt;5 metastatic lesions), spread to other distant&#xD;
             abdominal organs, peritoneal metastasis, spread to extra-abdominal organs.&#xD;
&#xD;
          -  No evidence of extension of the tumor into the celiac axis or superior mesenteric&#xD;
             artery (T4 disease).&#xD;
&#xD;
          -  intraoperative findings with:&#xD;
&#xD;
          -  tumor assessed as potentially locally resectable.&#xD;
&#xD;
          -  no signs of peritoneal metastasis or tumor manifestations outside of the pancreas and&#xD;
             the liver.&#xD;
&#xD;
          -  frozen section: adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extrapancreatic disease (except minimal metastatic disease of the liver, see above)&#xD;
&#xD;
          -  concomitant venous infiltration and minimal metastatic disease&#xD;
&#xD;
          -  extension of the tumor into the celiac axis or superior mesenteric artery&#xD;
&#xD;
          -  life expectancy of less than 3 months&#xD;
&#xD;
          -  previous or concurrent malignancy diagnosis, except non-melanoma skin cancer and in&#xD;
             situ carcinoma of the cervix&#xD;
&#xD;
          -  conditions potentially hampering compliance (also inclusion criteria)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Surgery and Institute of Statistics Klinikum rechts der Isar der Technischen Universität München Ismaningerstrasse 22 81675 München, Germany</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <keyword>Pancreatic cancer</keyword>
  <keyword>metastasis</keyword>
  <keyword>venous infiltration</keyword>
  <keyword>Pancreatic cancer with minimal metastatic disease or venous infiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

